Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Shareholders' (Deficit) Equity

v3.26.3
Condensed Consolidated Statements of Shareholders' (Deficit) Equity - USD ($)
$ in Thousands
Total
Series B Conversion
Preferred Class B
Common Stock
Common Stock
Series B Conversion
Preferred Stock
Preferred Class B
Preferred Stock
Preferred Class B
Series B Conversion
Additional Paid-in Capital
Additional Paid-in Capital
Series B Conversion
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Non-controlling Interest
Non-controlling Interest
Series B Conversion
Common stock, beginning balance (in shares) at Dec. 31, 2024       29,761,000                  
Beginning balance at Dec. 31, 2024 $ 285,868     $ 298   $ 0   $ 542,392   $ (2,732) $ (338,230) $ 84,140  
Preferred stock, beginning balance (in shares) at Dec. 31, 2024           10,000              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net income (loss) (61,191)                   (50,637) (10,554)  
Foreign currency translation adjustments 265                 265      
Series B conversions (in shares)         585,000   (1,000)            
Series B conversions   $ 0     $ 6       $ 1,208       $ (1,214)
Share-based compensation expense 2,958             2,958          
Issuance of share-based awards (in shares)       97,000                  
Payment of minimum tax withholdings on share-based awards and other (in shares)       (30,000)                  
Payment of minimum tax withholdings on share-based awards (894)                   (894)    
Common stock, ending balance (in shares) at Mar. 31, 2025       30,413,000                  
Preferred stock, ending balance (in shares) at Mar. 31, 2025           9,000              
Ending balance at Mar. 31, 2025 227,006     $ 304   $ 0   546,558   (2,467) (389,761) 72,372  
Common stock, beginning balance (in shares) at Dec. 31, 2024       29,761,000                  
Beginning balance at Dec. 31, 2024 285,868     $ 298   $ 0   542,392   (2,732) (338,230) 84,140  
Preferred stock, beginning balance (in shares) at Dec. 31, 2024           10,000              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net income (loss) (105,312)                        
Foreign currency translation adjustments 4,856                        
Common stock, ending balance (in shares) at Sep. 30, 2025       31,205,000                  
Preferred stock, ending balance (in shares) at Sep. 30, 2025           8,000              
Ending balance at Sep. 30, 2025 195,842     $ 312   $ 0   556,101   2,124 (418,753) 56,058  
Common stock, beginning balance (in shares) at Mar. 31, 2025       30,413,000                  
Beginning balance at Mar. 31, 2025 227,006     $ 304   $ 0   546,558   (2,467) (389,761) 72,372  
Preferred stock, beginning balance (in shares) at Mar. 31, 2025           9,000              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net income (loss) (20,364)                   (12,583) (7,781)  
Foreign currency translation adjustments 4,561                 4,561      
Series B conversions (in shares)         80,000                
Series B conversions   0     $ 1       143       (144)
Share-based compensation expense 4,711             4,711          
Issuance of share-based awards (in shares)       99,000                  
Payment of minimum tax withholdings on share-based awards and other (in shares)       (2,000)                  
Payment of minimum tax withholdings on share-based awards (107)                   (107)    
Common stock issued under employee stock purchase plan (in shares)       17,000                  
Common stock issued under employee stock purchase plan 434     $ 1       433          
Common stock, ending balance (in shares) at Jun. 30, 2025       30,607,000                  
Preferred stock, ending balance (in shares) at Jun. 30, 2025           9,000              
Ending balance at Jun. 30, 2025 216,241     $ 306   $ 0   551,845   2,094 (402,451) 64,447  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net income (loss) (23,757)                   (16,250) (7,507)  
Foreign currency translation adjustments 30                 30      
Series B conversions (in shares)         554,000   (1,000)            
Series B conversions   0     $ 6       876       (882)
Share-based compensation expense 3,380             3,380          
Issuance of share-based awards (in shares)       49,000                  
Payment of minimum tax withholdings on share-based awards and other (in shares)       (5,000)                  
Payment of minimum tax withholdings on share-based awards (52)                   (52)    
Common stock, ending balance (in shares) at Sep. 30, 2025       31,205,000                  
Preferred stock, ending balance (in shares) at Sep. 30, 2025           8,000              
Ending balance at Sep. 30, 2025 $ 195,842     $ 312   $ 0   556,101   2,124 (418,753) 56,058  
Common stock, beginning balance (in shares) at Dec. 31, 2025 31,327,000     31,327,000                  
Beginning balance at Dec. 31, 2025 $ 161,664     $ 313   $ 0   559,551   580 (447,100) 48,320  
Preferred stock, beginning balance (in shares) at Dec. 31, 2025 0   9,000     9,000              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net income (loss) $ (40,198)                   (34,319) (5,879)  
Foreign currency translation adjustments (2,046)                 (1,610)   (436)  
Series B conversions (in shares)         133,000                
Series B conversions   0     $ 1       729       (730)
Share-based compensation expense 3,541             3,541          
Issuance of share-based awards (in shares)       191,000                  
Issuance of share-based awards 0     $ 2       (2)          
Payment of minimum tax withholdings on share-based awards and other (in shares)       (53,000)                  
Payment of minimum tax withholdings on share-based awards and other (685)             807     (1,492)    
Common stock, ending balance (in shares) at Mar. 31, 2026       31,598,000                  
Preferred stock, ending balance (in shares) at Mar. 31, 2026           9,000              
Ending balance at Mar. 31, 2026 $ 122,276     $ 316   $ 0   564,626   (1,030) (482,911) 41,275  
Common stock, beginning balance (in shares) at Dec. 31, 2025 31,327,000     31,327,000                  
Beginning balance at Dec. 31, 2025 $ 161,664     $ 313   $ 0   559,551   580 (447,100) 48,320  
Preferred stock, beginning balance (in shares) at Dec. 31, 2025 0   9,000     9,000              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net income (loss) $ (277,009)                        
Foreign currency translation adjustments $ (490)                        
Common stock, ending balance (in shares) at Sep. 30, 2026 33,750,000     33,750,000                  
Preferred stock, ending balance (in shares) at Sep. 30, 2026 0   7,000     7,000              
Ending balance at Sep. 30, 2026 $ (108,941)     $ 337   $ 0   578,788   140 (679,001) (9,205)  
Common stock, beginning balance (in shares) at Mar. 31, 2026       31,598,000                  
Beginning balance at Mar. 31, 2026 122,276     $ 316   $ 0   564,626   (1,030) (482,911) 41,275  
Preferred stock, beginning balance (in shares) at Mar. 31, 2026           9,000              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net income (loss) (245,931)                   (207,300) (38,631)  
Foreign currency translation adjustments (135)                 (231)   96  
Series B conversions (in shares)         2,059,000   (2,000)            
Series B conversions   $ 0     $ 21       $ 9,955       $ (9,976)
Share-based compensation expense 491             491          
Issuance of share-based awards (in shares)       55,000                  
Payment of minimum tax withholdings on share-based awards and other (in shares)       (5,000)                  
Payment of minimum tax withholdings on share-based awards and other (101)             12     (113)    
Common stock issued under employee stock purchase plan (in shares)       29,000                  
Common stock issued under employee stock purchase plan 734             734          
Common stock, ending balance (in shares) at Jun. 30, 2026       33,736,000                  
Preferred stock, ending balance (in shares) at Jun. 30, 2026           7,000              
Ending balance at Jun. 30, 2026 (122,666)     $ 337   $ 0   575,818   (1,261) (690,324) (7,236)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net income (loss) 9,120                   11,379 (2,259)  
Foreign currency translation adjustments 1,691                 1,401   290  
Share-based compensation expense 2,967             2,967          
Issuance of share-based awards (in shares)       16,000                  
Payment of minimum tax withholdings on share-based awards and other (in shares)       (2,000)                  
Payment of minimum tax withholdings on share-based awards and other $ (53)             3     (56)    
Common stock, ending balance (in shares) at Sep. 30, 2026 33,750,000     33,750,000                  
Preferred stock, ending balance (in shares) at Sep. 30, 2026 0   7,000     7,000              
Ending balance at Sep. 30, 2026 $ (108,941)     $ 337   $ 0   $ 578,788   $ 140 $ (679,001) $ (9,205)